Brief: Pharmaust Says Successfully Completed A Pre-Ind Meeting With FDA
16/02/2024 01:31
Feb 16 (Reuters) - Pharmaust Ltd PAA.AX :
* SUCCESSFULLY COMPLETED A PRE-IND MEETING WITH FDA
* FDA GAVE POSITIVE FEEDBACK AND OUTLINED PATH REQUIRED TO
POTENTIALLY RECEIVE ACCELERATED AND FULL APPROVAL OF MONEPANTEL
Source text for Eikon: ID:nASX26GPtL
Further company coverage: PAA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO